-
公开(公告)号：US09226929B2
公开(公告)日：2016-01-05
申请号：US14002730
申请日：2012-03-01
Applicant: Gerd Rühter , Uwe Koch , Peter Nussbaumer , Carsten Schulz-Fademrecht , Jan Eickhoff
Inventor： Gerd Rühter , Uwe Koch , Peter Nussbaumer , Carsten Schulz-Fademrecht , Jan Eickhoff
IPC: C07D251/12 , C07D401/04 , C07D403/04 , C07D513/04 , A61K31/5377 , A61K31/53 , A61K31/5355 , C07D251/48 , C07D471/04 , C07D487/04 , C07D495/04 , A61K45/06 , C07D403/14 , C07D413/04
CPC classification number: A61K31/5377 , A61K31/53 , A61K31/5355 , A61K45/06 , C07D251/48 , C07D401/04 , C07D403/04 , C07D403/14 , C07D413/04 , C07D471/04 , C07D487/04 , C07D495/04 , C07D513/04 , A61K2300/00
Abstract: The present invention relates to disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted triazine derivatives as inhibitors for a protein kinase.
Abstract translation: 本发明涉及二取代的三嗪衍生物和/或其药学上可接受的盐，这些衍生物作为药物活性剂的用途，特别是用于预防和/或治疗感染性疾病，包括机会性疾病，免疫疾病，自身免疫性疾病，心血管疾病 ，细胞增殖性疾病，炎症，勃起功能障碍和中风，以及含有至少一种所述二取代的三嗪衍生物和/或其药学上可接受的盐的药物组合物。 此外，本发明涉及所述二取代三嗪衍生物作为蛋白激酶的抑制剂的用途。
-
公开(公告)号：US20140179662A1
公开(公告)日：2014-06-26
申请号：US14002730
申请日：2012-03-01
Applicant: Gerd Rühter , Uwe Koch , Peter Nussbaumer , Carsten Schulz-Fademrecht , Jan Eickhoff
Inventor： Gerd Rühter , Uwe Koch , Peter Nussbaumer , Carsten Schulz-Fademrecht , Jan Eickhoff
IPC: C07D513/04 , C07D401/04 , A61K31/53 , C07D413/04 , C07D487/04 , C07D403/04 , C07D403/14 , C07D471/04 , C07D495/04 , A61K45/06 , A61K31/5377
CPC classification number: A61K31/5377 , A61K31/53 , A61K31/5355 , A61K45/06 , C07D251/48 , C07D401/04 , C07D403/04 , C07D403/14 , C07D413/04 , C07D471/04 , C07D487/04 , C07D495/04 , C07D513/04 , A61K2300/00
Abstract: The present invention relates to disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted triazine derivatives as inhibitors for a protein kinase.
Abstract translation: 本发明涉及二取代的三嗪衍生物和/或其药学上可接受的盐，这些衍生物作为药物活性剂的用途，特别是用于预防和/或治疗感染性疾病，包括机会性疾病，免疫疾病，自身免疫性疾病，心血管疾病 ，细胞增殖性疾病，炎症，勃起功能障碍和中风，以及含有至少一种所述二取代的三嗪衍生物和/或其药学上可接受的盐的药物组合物。 此外，本发明涉及所述二取代三嗪衍生物作为蛋白激酶的抑制剂的用途。
-
公开(公告)号：US08152016B2
公开(公告)日：2012-04-10
申请号：US10589319
申请日：2004-04-07
Applicant: Manfred Berndt , Jose-Angel Mora-Fillat , Jan Eickhoff
Inventor： Manfred Berndt , Jose-Angel Mora-Fillat , Jan Eickhoff
CPC classification number: B01L3/50853 , B01L2300/044 , B01L2300/049 , B01L2300/0829 , B01L2400/0638 , B01L2400/065 , Y10T137/9247
Abstract: A cover for sealing a container and preferably containers for a well plate. The cover is comprised of at least a top layer and a bottom layer structured in a way to form a recloseable aperture. Preferably, each of the layers comprise a recloseable aperture structured as flap, damper, baffle or butterfly valve respectively, wherein the recloseable apertures are arranged on top of each other. In a preferred embodiment of the invention a third moveable layer is arranged between the top and the bottom layer. By moving the middle layer, the aperture in the cover can be closed.
Abstract translation: 用于密封容器并且优选用于井板的容器的盖。 该覆盖物由至少一层顶层和一底层构成，以形成可再封闭孔。 优选地，每个层包括分别构造为折翼，阻尼器，挡板或蝶阀的可再封闭的孔，其中可再封闭的孔布置在彼此的顶部。 在本发明的优选实施例中，第三可移动层布置在顶层和底层之间。 通过移动中间层，可以关闭盖子中的孔。
-
公开(公告)号：USD647537S1
公开(公告)日：2011-10-25
申请号：US29372588
申请日：2010-12-10
Applicant: Kurt Mehnert , Jan Eickhoff
Designer： Kurt Mehnert , Jan Eickhoff
-
公开(公告)号：US20080190840A1
公开(公告)日：2008-08-14
申请号：US11547696
申请日：2005-02-03
Applicant: Jan Eickhoff , Patrick Mueller , Jose Angel Mora-Fillat , Karsten Kraiczek , Kevin Killeen , Hongfeng Yin
Inventor： Jan Eickhoff , Patrick Mueller , Jose Angel Mora-Fillat , Karsten Kraiczek , Kevin Killeen , Hongfeng Yin
CPC classification number: B01L3/502753 , Y10T156/10
Abstract: A microfluidic device comprising at least one inlet port, at least one flow path coupled to the inlet port, and at least one fluid separation element coupled to the flow path, wherein the fluid separation element comprises a packing material and is adapted for separating different components of a fluid, wherein the microfluidic device comprises at least one retaining device for keeping the packing material of the fluid separation element fixed in place and protecting the microfluidic device from debris polluting the analyte.
Abstract translation: 一种微流体装置，包括至少一个入口端口，连接到入口端口的至少一个流动路径，以及耦合到流动路径的至少一个流体分离元件，其中流体分离元件包括填充材料，并且适于分离不同的部件 的流体，其中所述微流体装置包括至少一个保持装置，用于将所述流体分离元件的包装材料固定就位并保护所述微流体装置免受污染所述分析物的碎屑。
-
Patent Agency Ranking
公开(公告)号：US20150329537A2
公开(公告)日：2015-11-19
申请号：US14240329
申请日：2012-08-22
Applicant: Axel Choidas , Bert Klebl , Peter Habenberger , Jan Eickhoff , Roman Thomas , Johannes Heuckmann
Inventor： Axel Choidas , Bert Klebl , Peter Habenberger , Jan Eickhoff , Roman Thomas , Johannes Heuckmann
IPC: C07D471/04 , C07D405/10 , C07D401/12 , C07D403/04 , C07D403/12 , C07C53/18 , C07D213/40 , C07D251/16 , C07D401/04
CPC classification number: C07C53/18 , A61K31/4418 , A61K31/53 , C07D213/40 , C07D213/74 , C07D251/16 , C07D251/22 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/10 , C07D471/04
Abstract: The present invention relates to a CDK9 inhibitor, especially a selective CDK9 inhibitor, for use in treating, ameliorating and/or preventing midline carcinoma. Also corresponding methods for treating, preventing or ameliorating midline carcinoma are subject of the present invention. Preferably, NUT midline carcinoma is treated with the CDK9 inhibitors in accordance with the present invention.
Abstract translation: 本发明涉及用于治疗，改善和/或预防中线癌症的CDK9抑制剂，特别是选择性CDK9抑制剂。 用于治疗，预防或改善中线癌的相应方法也是本发明的主题。 优选地，根据本发明，用CDK9抑制剂处理NUT中线癌。
-
公开(公告)号：US20140303167A1
公开(公告)日：2014-10-09
申请号：US14240329
申请日：2012-08-22
Applicant: Axel Choidas , Bert Klebl , Peter Habenberger , Jan Eickhoff , Roman Thomas , Johannes Heuckmann
Inventor： Axel Choidas , Bert Klebl , Peter Habenberger , Jan Eickhoff , Roman Thomas , Johannes Heuckmann
IPC: C07D471/04 , C07D405/10 , C07D401/12 , C07D403/04 , C07D403/12 , C07C53/18 , C07D213/40 , C07D251/16 , C07D401/04
CPC classification number: C07C53/18 , A61K31/4418 , A61K31/53 , C07D213/40 , C07D213/74 , C07D251/16 , C07D251/22 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/10 , C07D471/04
Abstract: The present invention relates to a CDK9 inhibitor, especially a selective CDK9 inhibitor, for use in treating, ameliorating and/or preventing midline carcinoma. Also corresponding methods for treating, preventing or ameliorating midline carcinoma are subject of the present invention. Preferably, NUT midline carcinoma is treated with the CDK9 inhibitors in accordance with the present invention.
Abstract translation: 本发明涉及用于治疗，改善和/或预防中线癌症的CDK9抑制剂，特别是选择性CDK9抑制剂。 用于治疗，预防或改善中线癌的相应方法也是本发明的主题。 优选地，根据本发明，用CDK9抑制剂处理NUT中线癌。
-
公开(公告)号：US20130079345A1
公开(公告)日：2013-03-28
申请号：US13636448
申请日：2011-03-20
Applicant: Jan Eickhoff , Peter Nussbaumer , Gerd Ruhter , Carsten Schultz-Fademrecht , Ulrich Lucking , Axel Choidas , Bert Klebl
Inventor： Jan Eickhoff , Peter Nussbaumer , Gerd Ruhter , Carsten Schultz-Fademrecht , Ulrich Lucking , Axel Choidas , Bert Klebl
IPC: C07D251/16 , C07D405/10 , C07D401/12 , A61K45/06 , C07D413/10 , A61K31/5377 , C07D401/10 , C07D403/12 , A61K31/53 , C07D401/04
CPC classification number: C07D251/16 , A61K31/53 , A61K31/5377 , A61K45/06 , C07D251/22 , C07D401/04 , C07D401/10 , C07D401/12 , C07D403/12 , C07D405/10 , C07D407/04 , C07D413/10
Abstract: The present invention relates to disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted triazine derivatives as inhibitors for a protein kinase.
Abstract translation: 本发明涉及二取代的三嗪衍生物和/或其药学上可接受的盐，这些衍生物作为药物活性剂的用途，特别是用于预防和/或治疗感染性疾病，包括机会性疾病，免疫疾病，自身免疫性疾病，心血管疾病 ，细胞增殖性疾病，炎症，勃起功能障碍和中风，以及含有至少一种所述二取代的三嗪衍生物和/或其药学上可接受的盐的药物组合物。 此外，本发明涉及所述二取代三嗪衍生物作为蛋白激酶的抑制剂的用途。
-
公开(公告)号：US08232283B2
公开(公告)日：2012-07-31
申请号：US13105957
申请日：2011-05-12
Applicant: Andreas Schoop , Alexander Backes , Joachim Vogt , Lars Neumann , Jan Eickhoff , Stefan Hannus , Kerrin Hansen , Peter Amon , Igor Ivanov , Matthias Borgmann , Chase Smith , Arthur F. Kluge , Krishan Murthi , Rebecca Casaubon
Inventor： Andreas Schoop , Alexander Backes , Joachim Vogt , Lars Neumann , Jan Eickhoff , Stefan Hannus , Kerrin Hansen , Peter Amon , Igor Ivanov , Matthias Borgmann , Chase Smith , Arthur F. Kluge , Krishan Murthi , Rebecca Casaubon
IPC: C07D471/04 , A61K31/505 , A61P35/00
CPC classification number: C07D471/04
Abstract: The present invention provides derivatives of pyrido[2,3-d]pyrimidin-7-one. These compounds are inhibitors or kinases such as Raf, including compounds that show anti-proliferative activity, including against tumor cells, and are useful in the treatment of diseases including cancer.
Abstract translation: 本发明提供吡啶并[2,3-d]嘧啶-7-酮的衍生物。 这些化合物是抑制剂或激酶如Raf，包括显示抗增殖活性的化合物，包括抗肿瘤细胞，并且可用于治疗包括癌症在内的疾病。
-
公开(公告)号：USD603807S1
公开(公告)日：2009-11-10
申请号：US29313430
申请日：2009-01-06
Applicant: Kurt Mehnert , Jan Eickhoff
Designer： Kurt Mehnert , Jan Eickhoff
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.018 seconds)
